Research ExplorerPublicationsOutcome in dedifferentiated chondrosarcoma for patients trea...

Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study

Standard

Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. / Hompland, Ivar; Ferrari, Stefano; Bielack, Stefan; Palmerini, Emanuela; Hall, Kirsten S; Picci, Pierro; Hecker-Nolting, Stefanie; Donati, Davide M; Blattmann, Claudia; Bjerkehagen, Bodil; Staals, Eric; Kager, Leo; Gambarotti, Marco; Kühne, Thomas; Eriksson, Mikael; Ferraresi, Virginia; Kevric, Matthias; Biagini, Roberto; Baumhoer, Daniel; Brosjø, Otte; Comandone, Alessandro; Schwarz, Rudolf; Bertulli, Rossella; Kessler, Torsten; Hansson, Lina; Apice, Gaetano; Heydrich, Björn-N; Setola, Elisabetta; Flörcken, Anne; Ruggieri, Pietro; Krasniqi, Fatime; Hofmann-Wackersreuther, Gerda; Casali, Paolo; Reichardt, Peter; Smeland, Sigbjørn.

In: EUR J CANCER, Vol. 151, 07.2021, p. 150-158.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hompland, I, Ferrari, S, Bielack, S, Palmerini, E, Hall, KS, Picci, P, Hecker-Nolting, S, Donati, DM, Blattmann, C, Bjerkehagen, B, Staals, E, Kager, L, Gambarotti, M, Kühne, T, Eriksson, M, Ferraresi, V, Kevric, M, Biagini, R, Baumhoer, D, Brosjø, O, Comandone, A, Schwarz, R, Bertulli, R, Kessler, T, Hansson, L, Apice, G, Heydrich, B-N, Setola, E, Flörcken, A, Ruggieri, P, Krasniqi, F, Hofmann-Wackersreuther, G, Casali, P, Reichardt, P & Smeland, S 2021, 'Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study', EUR J CANCER, vol. 151, pp. 150-158. https://doi.org/10.1016/j.ejca.2021.04.017

APA

Hompland, I., Ferrari, S., Bielack, S., Palmerini, E., Hall, K. S., Picci, P., Hecker-Nolting, S., Donati, D. M., Blattmann, C., Bjerkehagen, B., Staals, E., Kager, L., Gambarotti, M., Kühne, T., Eriksson, M., Ferraresi, V., Kevric, M., Biagini, R., Baumhoer, D., ... Smeland, S. (2021). Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. EUR J CANCER, 151, 150-158. https://doi.org/10.1016/j.ejca.2021.04.017

Vancouver

Hompland I, Ferrari S, Bielack S, Palmerini E, Hall KS, Picci P et al. Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. EUR J CANCER. 2021 Jul;151:150-158. https://doi.org/10.1016/j.ejca.2021.04.017

Bibtex

@article{5330b07be2e94450b30836aebfefe574,
title = "Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study",
abstract = "INTRODUCTION: The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion. Here, we present the outcome in patients with DDCS treated with intensive chemotherapy from the EUROpean Bone Over 40 Sarcoma Study.MATERIALS AND METHODS: The chemotherapy regimen included doxorubicin, ifosfamide and cisplatin. Postoperative methotrexate was added in case of poor histological response. Toxicity was graded based on the National Cancer Institute expanded common toxicity criteria, version 2.0, and survival was analysed using Kaplan-Meier curves, log-rank tests and univariate Cox regression models.RESULTS: Fifty-seven patients with DDCS (localised, 34 [60%]; metastatic, 23 [40%]) aged 42-65 years were included. Surgical complete remission (SCR) was achieved in 36 (63%) patients. The median overall survival (OS) was 24 months (95% confidence interval, 22-25), and the 5-year OS was 39%. Patients with extremity localisation had a 5-year OS of 49% compared with 29% in patients with a central tumour (P = 0.08). Patients with localised disease had a 5-year OS of 46%, whereas patients with metastatic disease had a 5-year OS of 29% (P = 0.12). Patients in SCR had a 5-year OS of 49%, whereas patients not in SCR had a 5-year OS of 23% (P = 0.004). Chemotherapy toxicity was considerable but manageable. There was no treatment-related death, and 39 (70%) patients received ≥6 cycles of the planned nine chemotherapy cycles.CONCLUSIONS: Adding intensive chemotherapy to surgery for treatment of DDCS is feasible and shows favourable survival data compared with previous reports. With the limitations of data from a non-controlled trial, we conclude that chemotherapy could be considered in the management of patients aged >40 years.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Bone Neoplasms/mortality, Cell Dedifferentiation, Chemotherapy, Adjuvant, Chondrosarcoma/mortality, Disease-Free Survival, Europe, Feasibility Studies, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy/adverse effects, Prospective Studies, Time Factors",
author = "Ivar Hompland and Stefano Ferrari and Stefan Bielack and Emanuela Palmerini and Hall, {Kirsten S} and Pierro Picci and Stefanie Hecker-Nolting and Donati, {Davide M} and Claudia Blattmann and Bodil Bjerkehagen and Eric Staals and Leo Kager and Marco Gambarotti and Thomas K{\"u}hne and Mikael Eriksson and Virginia Ferraresi and Matthias Kevric and Roberto Biagini and Daniel Baumhoer and Otte Brosj{\o} and Alessandro Comandone and Rudolf Schwarz and Rossella Bertulli and Torsten Kessler and Lina Hansson and Gaetano Apice and Bj{\"o}rn-N Heydrich and Elisabetta Setola and Anne Fl{\"o}rcken and Pietro Ruggieri and Fatime Krasniqi and Gerda Hofmann-Wackersreuther and Paolo Casali and Peter Reichardt and Sigbj{\o}rn Smeland",
note = "Copyright {\textcopyright} 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.",
year = "2021",
month = jul,
doi = "10.1016/j.ejca.2021.04.017",
language = "English",
volume = "151",
pages = "150--158",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study

AU - Hompland, Ivar

AU - Ferrari, Stefano

AU - Bielack, Stefan

AU - Palmerini, Emanuela

AU - Hall, Kirsten S

AU - Picci, Pierro

AU - Hecker-Nolting, Stefanie

AU - Donati, Davide M

AU - Blattmann, Claudia

AU - Bjerkehagen, Bodil

AU - Staals, Eric

AU - Kager, Leo

AU - Gambarotti, Marco

AU - Kühne, Thomas

AU - Eriksson, Mikael

AU - Ferraresi, Virginia

AU - Kevric, Matthias

AU - Biagini, Roberto

AU - Baumhoer, Daniel

AU - Brosjø, Otte

AU - Comandone, Alessandro

AU - Schwarz, Rudolf

AU - Bertulli, Rossella

AU - Kessler, Torsten

AU - Hansson, Lina

AU - Apice, Gaetano

AU - Heydrich, Björn-N

AU - Setola, Elisabetta

AU - Flörcken, Anne

AU - Ruggieri, Pietro

AU - Krasniqi, Fatime

AU - Hofmann-Wackersreuther, Gerda

AU - Casali, Paolo

AU - Reichardt, Peter

AU - Smeland, Sigbjørn

N1 - Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

PY - 2021/7

Y1 - 2021/7

N2 - INTRODUCTION: The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion. Here, we present the outcome in patients with DDCS treated with intensive chemotherapy from the EUROpean Bone Over 40 Sarcoma Study.MATERIALS AND METHODS: The chemotherapy regimen included doxorubicin, ifosfamide and cisplatin. Postoperative methotrexate was added in case of poor histological response. Toxicity was graded based on the National Cancer Institute expanded common toxicity criteria, version 2.0, and survival was analysed using Kaplan-Meier curves, log-rank tests and univariate Cox regression models.RESULTS: Fifty-seven patients with DDCS (localised, 34 [60%]; metastatic, 23 [40%]) aged 42-65 years were included. Surgical complete remission (SCR) was achieved in 36 (63%) patients. The median overall survival (OS) was 24 months (95% confidence interval, 22-25), and the 5-year OS was 39%. Patients with extremity localisation had a 5-year OS of 49% compared with 29% in patients with a central tumour (P = 0.08). Patients with localised disease had a 5-year OS of 46%, whereas patients with metastatic disease had a 5-year OS of 29% (P = 0.12). Patients in SCR had a 5-year OS of 49%, whereas patients not in SCR had a 5-year OS of 23% (P = 0.004). Chemotherapy toxicity was considerable but manageable. There was no treatment-related death, and 39 (70%) patients received ≥6 cycles of the planned nine chemotherapy cycles.CONCLUSIONS: Adding intensive chemotherapy to surgery for treatment of DDCS is feasible and shows favourable survival data compared with previous reports. With the limitations of data from a non-controlled trial, we conclude that chemotherapy could be considered in the management of patients aged >40 years.

AB - INTRODUCTION: The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion. Here, we present the outcome in patients with DDCS treated with intensive chemotherapy from the EUROpean Bone Over 40 Sarcoma Study.MATERIALS AND METHODS: The chemotherapy regimen included doxorubicin, ifosfamide and cisplatin. Postoperative methotrexate was added in case of poor histological response. Toxicity was graded based on the National Cancer Institute expanded common toxicity criteria, version 2.0, and survival was analysed using Kaplan-Meier curves, log-rank tests and univariate Cox regression models.RESULTS: Fifty-seven patients with DDCS (localised, 34 [60%]; metastatic, 23 [40%]) aged 42-65 years were included. Surgical complete remission (SCR) was achieved in 36 (63%) patients. The median overall survival (OS) was 24 months (95% confidence interval, 22-25), and the 5-year OS was 39%. Patients with extremity localisation had a 5-year OS of 49% compared with 29% in patients with a central tumour (P = 0.08). Patients with localised disease had a 5-year OS of 46%, whereas patients with metastatic disease had a 5-year OS of 29% (P = 0.12). Patients in SCR had a 5-year OS of 49%, whereas patients not in SCR had a 5-year OS of 23% (P = 0.004). Chemotherapy toxicity was considerable but manageable. There was no treatment-related death, and 39 (70%) patients received ≥6 cycles of the planned nine chemotherapy cycles.CONCLUSIONS: Adding intensive chemotherapy to surgery for treatment of DDCS is feasible and shows favourable survival data compared with previous reports. With the limitations of data from a non-controlled trial, we conclude that chemotherapy could be considered in the management of patients aged >40 years.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Bone Neoplasms/mortality

KW - Cell Dedifferentiation

KW - Chemotherapy, Adjuvant

KW - Chondrosarcoma/mortality

KW - Disease-Free Survival

KW - Europe

KW - Feasibility Studies

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoadjuvant Therapy/adverse effects

KW - Prospective Studies

KW - Time Factors

U2 - 10.1016/j.ejca.2021.04.017

DO - 10.1016/j.ejca.2021.04.017

M3 - SCORING: Journal article

C2 - 33990016

VL - 151

SP - 150

EP - 158

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -